RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Rallybio Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.35+0.07 (+0.43%)

Close on Oct 19, 2026

Market cap: $94.80M
P/E (TTM): 2.1
Dividend yield: –

Rallybio Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	0.86	0.64	–	–	–	–
Research & Development	20	42	54	41	27	18
General & Administrative	14	20	25	27	19	7.67
Operating Expenses	34	61	79	68	46	25
Operating Income	-33	-60	-79	-68	-46	-25
Interest Expense	–	–	–	0	0.01	0.05
Income from Equity Investments	-0.87	-2.24	-2.04	-1.08	-1.51	-1.52
Other Non-Operating Income	25	4.96	6.41	2.31	0.14	0.36
Asset Impairment Charges	0	0	0	0	0	0
Pretax Income	-8.98	-56	-73	-66	-46	-25
Income Tax Expense	0	0	0	0	0	-0.02
Net Income incl. Noncontrolling Interests	–	–	–	–	-47	-26
Net Income	-8.98	-58	-75	-67	-47	-26
EPS (Basic)(per share)	-1.59	-10.61	-14.72	-16.72	-14.72	-12.16
EPS (Diluted)(per share)	-1.59	-10.61	-14.72	-16.72	-14.72	-12.16
Shares Outstanding (Basic, Weighted)(shares)	5.63	5.44	5.06	3.98	3.19	2.17
Shares Outstanding (Diluted, Weighted)(shares)	5.63	5.44	5.06	3.98	3.19	2.17
EBITDA	-33	-60	-79	-68	-46	-25

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -4291.5%
Net margin: 7051.2%
Return on equity, FY2025: -15.0%

Financial strength

Current ratio: 27.26
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2603.0%

Valuation

P/E ratio: 2.1
Price to sales: 146.74
Price to book: 1.00
Dividend yield: –